- Home
- SBFM vs BIAF Comparison
SBFM vs BIAF Comparison
Compare SBFM & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBFM
- BIAF
- Stock Information
- Founded
- SBFM 2006
- BIAF 2014
- Country
- SBFM United States
- BIAF United States
- Employees
- SBFM N/A
- BIAF N/A
- Industry
- SBFM Biotechnology: Pharmaceutical Preparations
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- SBFM Health Care
- BIAF Health Care
- Exchange
- SBFM Nasdaq
- BIAF Nasdaq
- Market Cap
- SBFM 6.7M
- BIAF 7.6M
- IPO Year
- SBFM N/A
- BIAF 2022
- Fundamental
- Price
- SBFM $1.75
- BIAF $2.71
- Analyst Decision
- SBFM Strong Buy
- BIAF Hold
- Analyst Count
- SBFM 1
- BIAF 1
- Target Price
- SBFM $7.00
- BIAF N/A
- AVG Volume (30 Days)
- SBFM 71.9K
- BIAF 7.4M
- Earning Date
- SBFM 11-04-2025
- BIAF 11-13-2025
- Dividend Yield
- SBFM N/A
- BIAF N/A
- EPS Growth
- SBFM N/A
- BIAF N/A
- EPS
- SBFM N/A
- BIAF N/A
- Revenue
- SBFM $36,341,741.00
- BIAF $7,681,059.00
- Revenue This Year
- SBFM $32.20
- BIAF N/A
- Revenue Next Year
- SBFM $32.74
- BIAF $20.04
- P/E Ratio
- SBFM N/A
- BIAF N/A
- Revenue Growth
- SBFM 19.22
- BIAF 4.99
- 52 Week Low
- SBFM $1.17
- BIAF $2.34
- 52 Week High
- SBFM $3.90
- BIAF $67.12
- Technical
- Relative Strength Index (RSI)
- SBFM 66.08
- BIAF 48.84
- Support Level
- SBFM $1.50
- BIAF $2.36
- Resistance Level
- SBFM $1.74
- BIAF $3.65
- Average True Range (ATR)
- SBFM 0.09
- BIAF 0.58
- MACD
- SBFM 0.01
- BIAF -0.23
- Stochastic Oscillator
- SBFM 96.84
- BIAF 7.12
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.